NZ335081A - Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer
- Google Patents
Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0Aexternal-prioritypatent/GB9626309D0/en
Priority claimed from GBGB9718160.6Aexternal-prioritypatent/GB9718160D0/en
Application filed by Merck & Co IncfiledCriticalMerck & Co Inc
Priority claimed from PCT/US1997/019225external-prioritypatent/WO1998018493A2/en
Publication of NZ335081ApublicationCriticalpatent/NZ335081A/en
A conjugate comprises a cytotoxic agent attached to an oligopeptide comprising a sequence of amino acids that is selectively proteolytically cleaved by free prostate specific antigen or an optical isomer or pharmaceutically acceptable salt thereof. The means of attachment between the cytotoxic agent and the oligopeptide is a covalent bond or through a chemical linker. The sequence of amino acids comprises at least one cyclic amino acid having a hydrophilic substituent The conjugate is useful for the treatment of prostate cancer.
NZ335081A1996-10-301997-10-27Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer
NZ335081A
(en)
Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer
Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer